| 1907 |
Establishment of Kirin Brewery Co., Ltd. |
| 1949 |
Establishment of Kyowa Hakko Kogyo Co., Ltd. as a secondary company of Kyowa Sangyo Co., Ltd, as part of industrial readjustment plans. |
| 1951 |
Introduced production technology of Streptomycin, an anti-tubercular drug, from US pharmaceutical company Merck & Co., Inc. and succeeded in its mass production. Contributed to the wiping out of tuberculosis in Japan (beginning of involvement in pharmaceutical business operations). |
| 1956 |
Success of isolation and commercially mass-production of the anticancer drug, Mitomycin C. Invention of the process of L-glutamic acid production by fermentation (a world first). |
| 1963 |
Initiation of full-scale involvement in the pharmaceutical business. Release of Mitomycin C, an anticancer drug, and Spiramycin, an antibiotic drug. |
| 1967 |
Release of 5-FU, an anticancer drug. |
| 1971 |
Release of Leunase, an anticancer drug. |
| 1982 |
The Research Institute for Production Development foundation begins full-scale research towards the commercialization of erythropoietin. |
| 1988 |
Supported the establishment in the U.S.A. of the La Jolla Institute for Allergy and Immunology (LIAI). |
| 1990 |
Release of ESPO®, an erythropoietin (EPO) drug. |
| 1991 |
Release of GRAN®, G-CSF drug. Release of Coniel, a remedy for hypertension and agina pectoris. |
| 1997 |
Establishment of fully human antibody production technology. |
| 2003 |
Establishment of BioWa, Inc. in the United States to promote Kyowa Hakko's therapeutic antibody business. |
| 2007 |
The launch of Kirin Pharma Company, Limited to accompany the adoption by Kirin Brewery Company, Limited of a pure holding company system. Release of NESP®, a long-acting erythropoietic stimulating drug. Established COMPLEGENT®, a novel antibody engineering technology that enhances the efficacy of antibodies, and licensed to BioWa, Inc, its subsidiary. Capital alliance between Kyowa Hakko Group and Kirin Group. |
| 2008 |
Release of REGPARA®, a drug for secondary hyperparathyroidism. Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd. Kyowa Hakko Kirin was formed through the merger of Kyowa Hakko Kogyo and Kirin Pharma. |
| 2009 |
Introduced 'Commitment to Life'. |
| 2011 |
Acquired ProStrakan Group plc. |
| 2012 |
Launch of Poteligeo® in Japan, a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL). |
| 2013 |
Launch of NOURIAST® tablets 20 mg in Japan, a novel antiparkinsonian agent. |
| 2014 |
ProStrakan Completes Acquisition of Archimedes. Launch of Sustained-Duration G-CSF Product G-LASTA® in Japan. |
| 2016 |
Rebranding Western Pharmaceutical Subsidiaries to 'Kyowa Kirin'. Launch of LUMICEF® for Psoriasis Treatment in Japan. |
| 2018 |
Crysvita® approved in the US and Europe, sales to start as a treatment for patients with X-linked hypophosphatemia. Poteligeo® approved in the US and Europe as a treatment for mycosis fungoides (MF) and Sézary syndrome (SS). |
| 2019 |
Trade name changed to current 'Kyowa Kirin Co., Ltd.' from Kyowa Hakko Kirin Co., Ltd. |
| 2020 |
Crysvita® launched in Japan for the treatment of FGF23-related Hypophosphatemic Rickets and Osteomalacia. |
| 2020 |
Nourianz™ launched in the US for use in Parkinson's disease. |
| 2020 |
Poteligeo® launched in Europe for the treatment for mycosis fungoides (MF) and Sézary syndrome (SS). |
| 2020 |
Crysvita® approved in the US for the treatment of tumor-induced osteomalacia (TIO). |
| 2021 |
New Vision toward 2030 designed to realize the creation and delivery of life-changing value. |
| 2021 |
Agreement reached with Amgen to jointly develop and commercialize KHK4083, a Kyowa Kirin-discovered anti-OX40 fully human monoclonal antibody. |
| 2021 |
Declared support for the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD). |
| 2022 |
Global DE&I Statement adopted with 40% of global leaders to be female by 2030. |
| 2022 |
An automated injection device "G-Lasta® Subcutaneous Injection 3.6 mg BodyPod" launched in Japan for the long-acting G-CSF preparation, G-Lasta®. |
| 2022 |
Q-TOWER, the new biopharmaceutical analysis facility completed at Takasaki Plant, Kyowa Kirin's major biopharmaceutical manufacturing site. |
| 2023 |
PHOZEVEL® approved in Japan for the treatment of Hyperphosphatemia in chronic kidney disease patients. |
| 2023 |
Kyowa Kirin announced the acquisition of UK company Orchard Therapeutics with strength in hematopoietic stem cell gene therapy. |
| 2024 |
Lenmeldy™ , an innovative hematopoietic stem cell (HSC) gene therapy, approved and launched in the United States. |
| 2024 |
A new biologics manufacturing plant decided to be established in North Carolina, the United States. |
| 2024 |
A global strategic collaboration signed to develop and commercialize menin inhibitor ziftomenib in acute leukemias with Kura Oncology. |
| 2025 |
Completion of the HB7 Building, a new biopharmaceutical DS (Drug Substance) manufacturing facility at the Takasaki Plant, to strengthen global manufacturing capacity and talent development. |
| 2025 |
FDA approval and U.S. launch of KOMZIFTI™ (ziftomenib) for adult AML (Acute Myeloid Leukemia). |
